Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TAK-385 in the Treatment of Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Premenopausal women~2. The participants must have dysmenorrhea and pelvic pain associated with endometriosis.~3. The participant has experienced a regular menstrual cycle.~4. The participant has been diagnosed with endometriosis by method a), b), or c).~   * Laparotomy~  * Laparoscopy~  * Chocolate cyst of the ovary confirmed by MRI~Exclusion Criteria:~1. Participants diagnosed with measurable uterine fibroids with the longest diameter of 3 cm or larger~2. Participants with lower abdominal pain due to irritable bowel syndrome or severe interstitial cystitis~3. Participants with a previous or current history of thyroid dysfunction~4. Participants with current or previous history of pelvic inflammatory disease~5. Participants with positive PAP smear test result conducted~6. Participants with a history of panhysterectomy or bilateral oophorectomy~7. Participants judged by investigator to have marked abnormal uterine bleeding or anovulatory bleeding~8. Participants with a previous or current history of a malignant tumor~9. Participants who have been treated with any of the following drugs: anticoagulant drug, antiplatelet drug, tranexamic acid, selective estrogen receptor modulator (SERM), activated vitamin D, other vitamin D, calcitonin, ipriflavone, steroid hormone, vitamin K, teriparatide,or denosumab~10. Participants who have been treated with any of the following drugs: oral contraceptive and sex hormone preparation, gonadotropin-releasing hormone (GnRH) analogue, dienogest, danazol, or aromatase inhibitor~11. Participants who have been treated with bisphosphonate preparation~12. Participants with a previous or current history of hypersensitivity or allergy to Leuplin, synthetic LH-RH, LH-RH derivatives, gelatin-containing formulations or food containing gelatin, or have a previous or current history of severe hypersensitivity or severe allergy to other drugs~13. Participants with non-diagnosable abnormal genital bleeding~14. Participants with a previous or current history of osteoporosis, bone mass loss, or other metabolic bone diseases~15. Participants with clinically significant cardiovascular disease or uncontrollable hypertension~16. Participants judged by investigator to be inappropriate to participate in this study based on the 12-lead electrocardiogram (ECG) findings~17. Participants with active liver disease or jaundice, or with alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin \> 1.5 times the upper limit of normal (ULN) in the clinical laboratory tests

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- TAK-385 10 mg QD (Type: EXPERIMENTAL): None
- TAK-385 20 mg QD (Type: EXPERIMENTAL): None
- TAK-385 40 mg QD (Type: EXPERIMENTAL): None
- Leuplin (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).